US Stock MarketDetailed Quotes

ZNTL Zentalis Pharmaceuticals

Watchlist
  • 2.070
  • +0.050+2.48%
Close Feb 28 16:00 ET
  • 2.070
  • 0.0000.00%
Post 20:01 ET
147.52MMarket Cap-0.83P/E (TTM)

About Zentalis Pharmaceuticals Company

Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. It develops a broad pipeline of product candidates with an initial focus on validated oncology targets with the potential to address large patient populations. The company was founded by Kevin D. Bunker and Cam Gallagher on December 23, 2014 and is headquartered in San Diego, CA.

Company Profile

SymbolZNTL
Company NameZentalis Pharmaceuticals
Listing DateApr 3, 2020
Issue Price18.00
Founded2014
CEOMs. Julie M. Eastland
MarketNASDAQ
Employees168
Fiscal Year Ends12-31
Address10275 Science Center Drive,Suite 200
CitySan Diego
ProvinceCalifornia
CountryUnited States of America
Zip Code92121
Phone1-858-263-4333

Company Executives

  • Name
  • Position
  • Salary
  • Julie M. Eastland
  • Chief Executive Officer, President and Director
  • --
  • Andrea Paul
  • Chief Legal Officer and Corporate Secretary
  • 2.63M
  • Dr. Diana F. Hausman, M.D.
  • Chief Medical Officer
  • 906.98K
  • Dr. Kyle Rasbach, PhD,Pharm.D.
  • Chief Business Officer
  • --
  • Dr. Mark Lackner, PhD
  • Chief Scientific Officer
  • --
  • Vincent Vultaggio
  • Principal Accounting Officer and Interim Principal Financial Officer
  • --
  • Scott D. Myers
  • Chairman of the Board
  • --
  • David M. Johnson
  • Chairman of the Board
  • 617.78K
  • Dr. Luke Nathaniel Walker, M.D.
  • Director
  • --
  • Dr. Jan Skvarka, PhD
  • Independent Director
  • 515.22K
  • Karan S. Takhar
  • Independent Director
  • --
  • Dr. Enoch Kariuki, Pharm.D.
  • Independent Director
  • 516.97K

Trending Stocks

Top Gaining Chinese Stocks Top Gaining Chinese Stocks
Unlock Now
Reassessing Chinese Assets
Following the introduction of China's groundbreaking DeepSeek technology, Wall Street giants have revised their investment outlooks for the Chinese market.
Discussing
Tesla's earnings caused fluctuations, what's your market outlook?
Tesla's Q4 2024 revenue was $25.71 billion, up 2% year-on-year but below expectations. Can Tesla's stock price keep rising in 2025 with Trum Show More